Skip to main content
Alison Boyce, MD, Pediatric Endocrinology, Bethesda, MD, NIH Clinical Center

AlisonMBoyceMD

Pediatric Endocrinology Bethesda, MD

Pediatric Bone Metabolism Disorders

Metabolic Bone Disorders Unit, NIDCR, National Institutes of Health

Dr. Boyce is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Boyce's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center/Eunice Kennedy Shriver NICHD
    National Institutes of Health Clinical Center/Eunice Kennedy Shriver NICHDFellowship, Pediatric Endocrinology, 2009 - 2012
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolResidency, Pediatrics, 2006 - 2009
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolClass of 2006
  • University of Virginia
    University of VirginiaB.S., Chemistry, 1998 - 2002

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2012 - 2024
  • MD State Medical License
    MD State Medical License 2012 - 2016
  • VA State Medical License
    VA State Medical License 2009 - 2014

Awards, Honors, & Recognition

  • Constellation Award Fibrous Dysplasia Foundation, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated with Disease Burden  
    Alison M Boyce, Jeffrey Tsai, Rachel I Gafni, Journal of Bone and Mineral Research
  • Fibrous Dysplasia/McCune-Albright Syndrome 2015 Feb 26 In: Pagon RA, Adam MP, Amemiya A, et al, editors  
    Boyce AM, Collins MT, GeneReviews, 1/1/2015
  • A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia  
    Boyce AM, Kelly MH, Brillante BA, Kushner H, Weintroub S, Riminucci M, Bianco P, Robey PG, Collins MT, Journal of Clinical Endocrinology and Metabolism, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398
    Collins MT, Bergwitz C, Aitcheson G, Blau J, Boyce AM, Gafni RI, Guthrie LC, Miranda F, Slosberg E, Graus Porta D, Hopmann C, Welaya K, Isaacs R, Miller C, American Society for Bone and Mineral Research, Seattle, WA, 1/1/2015
  • Parathyroid Hormone (PTH) 1-34 therapy decreases urinary citrate in hypoparathyroidism
    Gafni RI, Langman C, Guthrie LC, Brillante BA, James R, Yovetich N, Boyce AM, Collins MT, American Society for Bone and Mineral Research, Seattle, WA, 1/1/2015
  • A subtronchanteric femoral stress fracture following bisphosphonate treatment in an adolescent girl
    Boyce AM, Tosi LL, Gafni RI, International Conference on Children’s Bone Health; American Society for Bone and Mineral Research, Salzburg, Austria, 2015; Seattle, WA, 2015, 1/1/2015
  • Join now to see all

Lectures

  • Management of Pediatric Fibrous Dysplasia/McCune-Albright Syndrome 
    Oxford, United Kingdom - 1/1/2015
  • Endocrine Complications of Fibrous Dysplasia/McCune-Albright Syndrome 
    Oxford, United Kingdom - 1/1/2015
  • Meet the Expert Session: Managing Fibrous Dysplasia 
    Salzburg, Austria - 1/1/2015
  • Join now to see all

Other

Press Mentions

  • Mosaic Effects of Growth Hormone on Fibrous Dysplasia of Bone
    Mosaic Effects of Growth Hormone on Fibrous Dysplasia of BoneNovember 15th, 2018

Professional Memberships

  • Member
  • American Society for Bone and Mineral Research
    Member
  • Pediatric Endocrine Society
    Member
  • Society for Pediatric Research
    Member

Hospital Affiliations